These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9716166)

  • 1. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D; Rakicevic L; Kovac M; Radojkovic D
    Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
    Middendorf K; Göhring P; Huehns TY; Seidel D; Steinbeck G; Nikol S
    Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
    Rothbart H; Ohel G; Younis J; Lanir N; Brenner B
    J Matern Fetal Med; 1999; 8(5):228-30. PubMed ID: 10475506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis].
    Martínez Ara J; Gómez Rioja R; Riñón C; García Muñoz MS; Ruiz Caravaca ML; Miguel JL
    Nefrologia; 2000; 20(2):139-44. PubMed ID: 10853194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
    Taylor LJ; Oster RA; Fritsma GA; Tichenor PH; Reed CE; Eiland BM; Hudson CL; Marques MB
    Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of factor V Leiden mutations on prognosis in patients with acute myocardial infarction].
    Baykan M; Celik S; Uçar F; Kaplan S; Ovali E; Erdöl C
    Anadolu Kardiyol Derg; 2001 Dec; 1(4):242-5; AXIV. PubMed ID: 12101832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated protein C resistance in anterior ischaemic optic neuropathy.
    Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
    Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A].
    Reitsma PH; van de Stolpe A
    Ned Tijdschr Geneeskd; 2001 Sep; 145(38):1843-5. PubMed ID: 11593787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary.
    Balogh I; Póka R; Pfliegler G; Dékány M; Boda Z; Muszbek L
    Thromb Haemost; 1999 Apr; 81(4):660-1. PubMed ID: 10235459
    [No Abstract]   [Full Text] [Related]  

  • 14. Activated protein C resistance and factor V Leiden in Mexico.
    Majluf-Cruz A; Moreno-Hernández M; Ruiz-de-Chávez-Ochoa A; Monroy-García R; Majluf-Cruz K; Guardado-Mendoza R; Molina-Avila I; Isordia-Salas I; Corona-de la Peña N; Vargas-Vorackova F; Vela-Ojeda J; García-Chávez J
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):428-37. PubMed ID: 18160617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
    Rehak M; Rehak J; Müller M; Faude S; Faude F; Siegemund A; Krcova V; Slavik L; Hasenclever D; Scholz M; Wiedemann P
    Thromb Haemost; 2008 May; 99(5):925-9. PubMed ID: 18449423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
    El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
    Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
    Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
    Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor V Leiden mutation in one family of Chinese origin.
    Wu J; Gu J; Xu J; Wang J; Sun Z; Smirnov MD; Morrissey JH; Esmon N
    Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.